Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 47:1522-1529, doi:10.1016/j.jacc.2005.12.052 (Published online 24 March 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez, A. E.

Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis

The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study

Alfredo E. Rodriguez, MD, PhD, FACC*,*, Juan F. Granada, MD{dagger}, Máximo Rodriguez-Alemparte, MD*, Cesar F. Vigo, MD*, Juan Delgado, MD{dagger},1, Carlos Fernandez-Pereira, MD*, Antonio Pocovi, MD*, Alfredo M. Rodriguez-Granillo, BS*, Daryl Schulz, RTN{dagger}, Albert E. Raizner, MD, FACC{dagger}, Igor Palacios, MD, FACC{ddagger}, William O’Neill, MD, FACC§, Grzegorz L. Kaluza, MD, PhD{dagger}, Gregg Stone, MD, PhD, FACC|| for the ORAR II Investigators

* Otamendi Hospital, Buenos Aires, Argentina
{dagger} The Methodist Hospital Research Institute, Houston, Texas
{ddagger} Massachusetts General Hospital, Boston, Massachusetts
§ William Beaumont Hospital, Royal Oak, Michigan
|| Columbia University, New York, New York Dr.


Figure 1
View larger version (13K):

[in a new window]
 
Figure 1 Kaplan-Meier curves showing event-free survival from target lesion revascularization (A), target vessel revascularization (B), and major adverse cardiovascular events (C) for the global follow-up. The p values were calculated using the log-rank test.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement